Approximately 30% of patients that are treated for primary prostate cancer will develop recurrent disease that presents either as biochemical recurrence (rising prostate-specific antigen (PSA) levels) or positive scans/biopsies of local or distant metastases [1,2]. This evidence concerns the gene KLK3 and prostate cancer.